Phibro Animal Health Sales Gain, but Costs and Currency Pose Risks
Animal Health growth and higher vaccine sales supported Phibro in fiscal 2026, while foreign-exchange losses and input costs weighed on results.
Key takeaways
- Phibro’s Animal Health sales rose 21% to $1.16 billion in fiscal 2026.
- Vaccine sales increased 14% to $156 million.
- Foreign-currency losses reached $12.6 million in fiscal 2026.
- Zacks’ fiscal 2027 EPS estimate rose 2% to $3.50 over the past 30 days.
Phibro Animal Health’s Animal Health segment grew 21% in fiscal 2026, reaching $1.16 billion in net sales. Growth came amid demand for legacy products and the addition of Zoetis medicated feed additives, while higher costs and currency swings remain risks.
The acquired feed-additive portfolio contributed $358.2 million in fiscal 2026 sales. Phibro also reported growth in vaccines and nutritional specialty products. Vaccine sales rose 14% to $156 million, with the company increasing manufacturing capacity in Ireland and Israel; related capital spending is expected to rise in fiscal 2027 and 2028.
Mineral Nutrition sales increased 11% to $282.3 million as demand rose for copper, zinc and other trace minerals. Adjusted EBITDA for the segment grew 4% to $21.7 million, as higher unit costs offset much of the benefit from increased sales.
Zacks Equity Research cited trade-policy changes, supply-chain disruption and higher input and distribution costs as risks. Phibro’s foreign-currency losses were $12.6 million in fiscal 2026, compared with $7.9 million in fiscal 2025.
The Zacks Consensus Estimate for Phibro’s fiscal 2027 earnings per share rose 2% over the past 30 days to $3.50. Its revenue estimate is $1.58 billion, which Zacks says would represent a 3.4% increase from the prior year’s reported figure.
This article was produced with the help of AI technology. Source: Yahoo Finance
